Rotavirus vaccine coverage, completion, and compliance: A systematic literature review

Figures

• 

  Figure 1.. PRISMA flow diagram of the study selection procedure. 2D-RV, Rotarix™ two-dose RVV; 3D-RV, RotaTeq® three-dose RVV; PRISMA, preferred reporting items for systematic literature reviews and meta-analyses; RVV, rotavirus vaccine; UNICEF, united nations children’s fund; WHO, World Health Organization.*Main exclusion criteria during the record-screening phase are described in section 2.2.†Included 74 publications in this review, 71 being unique studies.‡All four included studies were identified through one systematic review and present results from Ethiopia.

• 

  Figure 2.. 2D-RV and 3D-RV full-coverage rates by country and the period after introduction into the NIP. *averaged full coverage: Australia 2008–2009 (one study on indigenous population 67.1% and nonindigenous population 84.1% for 3D-RV and 76.1% and 86.9%, respectively for 2D-RV); Mexico (two studies reporting 89.0% and 89.0% for 2D-RV in 2010 and one study reporting 75.6%, 77.3%, 78.0%, 91.6%, and 64.2% for national, North, center, Mexico City, and south, respectively for 2D-RV in 2010–2011 and 61.0%, 59.4%, 65.0%, 72.3%, and 52.7% for national, North, center, Mexico City, and south, respectively in 2012–2013). Detailed data regarding full coverage and study characteristics are presented in table S2. Where the 2D-RV and 3D-RV bars are placed against each other, the 2D-RV and 3D-RV full-coverage rates were reported in the same country, either during different time periods when different RVVs were used or in different subpopulations or regions at the same time (i.e., there was no direct head-to-head comparison). 2D-RV, Rotarix™ two-dose RVV; 3D-RV, RotaTeq® three-dose RVV; ACT, Australian capital Territory; NIP, national immunization program; NSW, New South Wales; NT, northern Territory;…

• 

  Figure 3.. 2D-RV and 3D-RV completion rates by country and the period after introduction into the NIP. Detailed data regarding completion and study characteristics are presented in table S3. Where the 2D-RV and 3D-RV bars are placed against each other, the 2D-RV and 3D-RV completion rates were reported in the same country, either during different time periods when different RVVs were used or in different subpopulations or regions at the same time (i.e., there was no direct head-to-head comparison). 2D-RV, Rotarix™ two-dose RVV; 3D-RV, RotaTeq® three-dose RVV; ACIP, advisory committee on immunization Practices; NIP, national immunization program; PI, prescribing information; RVV, rotavirus vaccine.

• 

  Figure 4.. 2D-RV and 3D-RV compliance by country and the period after introduction into the NIP. Detailed data regarding compliance and study characteristics are presented in table S4. Only the last year or overall period is reported in the figure; yearly data, if available, are in table S4. Where the 2D-RV and 3D-RV bars are placed against each other, the 2D-RV and 3D-RV compliance rates were reported in the same country, either during different time periods when different RVVs were used or in different subpopulations or regions at the same time (i.e., there was no direct head-to-head comparison). 2D-RV, Rotarix™ two-dose RVV; 3D-RV, RotaTeq® three-dose RVV; ACIP, advisory committee on immunization Practices; IIS, immunization information systems and sentinel sites; NIP, national immunization program; PI, prescribing information; RVV, rotavirus vaccine; VSD, vaccine safety datalink.